Bae Joon Seol, Kim Jason Yongha, Park Byung-Lae, Kim Jeong-Hyun, Kim Bomi, Park Chul Soo, Kim Bong-Jo, Lee Cheol-Soon, Lee Migyung, Choi Woo Hyuk, Shin Tae-Min, Hwang Jaeuk, Shin Hyoung Doo, Woo Sung-Il
aLaboratory of Translational Genomics, Samsung Genome Institute, Samsung Medical Center bLaboratory of Genomic Diversity, Department of Life Science cDepartment of Genetic Epidemiology, SNP Genetics Inc., Sogang University dDepartment of General Psychiatry, Seoul National Hospital eDepartment of Neuropsychiatry, Soonchunhyang University Hospital, Seoul fDepartment of Psychiatry, College of Medicine, Gyeongsang National University, Gyeongsang Nam Do gDepartment of Biomedical Engineering, Yonsei University, Wonju, Republic of Korea hResearch Institute for Basic Science, Sogang University, Shinsu-dong, Mapo-gu, Seoul, 121-742, Republic of Korea.
Psychiatr Genet. 2014 Oct;24(5):225-9. doi: 10.1097/YPG.0000000000000047.
Located on 6q15 and 1p36.11, cannabinoid receptor 1 (CNR1) and cannabinoid receptor 2 (CNR2) genes are considered to be a positional and functional candidate gene for the development of mental disorders such as schizophrenia because CNR1 is known as a regulator of dopamine signaling in the hippocampus and the cerebral cortex. However, few genetic studies have been carried out to investigate an association of CNR1 and CNR2 polymorphisms and the risk of schizophrenia. In this study, although the result indicates that CNR1 and CNR2 variations are unlikely to influence schizophrenia susceptibility in a Korean population, the findings would provide meaningful information for further genetic studies.
大麻素受体1（CNR1）基因和大麻素受体2（CNR2）基因分别位于6q15和1p36.11，被认为是精神疾病如精神分裂症发生发展的位置和功能候选基因，因为CNR1是海马体和大脑皮层中多巴胺信号的调节因子。然而，很少有基因研究来探究CNR1和CNR2基因多态性与精神分裂症风险之间的关联。在本研究中，尽管结果表明CNR1和CNR2基因变异不太可能影响韩国人群中精神分裂症的易感性，但这些发现将为进一步的基因研究提供有意义的信息。
